Krishna Institute of Medical Sciences has approved the issuance of 77,02,182 warrants on a preferential basis to its promoters and a promoter group entity. The resolution was passed by shareholders at the Extraordinary General Meeting (EGM) held on July 9, 2026, through Video Conferencing and Other Audio Visual Means. The company also approved the re-designation of Mr. Adwik Bollineni as Executive Director for a period of five years.

Voting Results Summary

The scrutinizer's report confirms that all resolutions were passed with the requisite majority. The preferential issue of warrants to Dr. Abhinay Bollineni, Mr. Adwik Bollineni, and Bharas Ventures LLP received 94.32% votes in favour. The re-designation of Mr. Adwik Bollineni was approved with 82.32% votes in favour, with votes from interested parties treated as invalid.

Resolution Details

The following table summarizes the voting results for the key resolutions:

Procedural Details

The remote e-voting facility was open from July 6, 2026, to July 8, 2026. A total of 402 members participated in the voting process, representing 31,67,34,800 shares. Mr. Krishna Rao Inturi, Proprietor of IKR & Associates, served as the scrutinizer for the meeting. The results have been submitted to the BSE and NSE.

Krishna Institute of Medical Sciences has received approval from the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) for the listing of 19,867,549 equity shares issued through a Qualified Institutions Placement (QIP). The shares, issued at a price of ₹755 per share, were allotted to eligible qualified institutional buyers following the issue's closure on June 19, 2026. The allotment includes a premium of ₹753 per equity share and incorporates a discount of ₹16.73 per share, equivalent to 2.17% of the floor price of ₹771.73.

The listing approvals, granted on June 22, 2026, by the NSE and subsequently by the BSE, pertain to equity shares of ₹2 each bearing distinctive numbers from 400138936 to 420006484. Trading in these shares will commence only after the company files the necessary confirmation letters from the depositories, CDSL and NSDL, regarding the crediting of shares to the beneficiaries' accounts. The company had previously secured board approval on March 11, 2026, and shareholder consent via postal ballot on April 15, 2026.

Issue Details

The Finance & Investment Committee approved the closure of the issue period and finalized the allocation during a meeting held on June 19, 2026. The committee determined the issue price in consultation with the book running lead managers, applying the permitted discount on the floor price calculated under Regulation 176(1) of the SEBI ICDR Regulations. The trading window for designated persons, which was closed since the issue opening, will reopen 48 hours after the determination of the issue price.